Randomized trial demonstrates reduced intraoperative blood loss in men undergoing TURP, suggesting effective prophylaxis.
Key Points
The study aims to evaluate the efficacy and safety of tranexamic acid in reducing bleeding complications during transurethral resection of the prostate.
Systematic review of Medline, Embase, and CENTRAL for randomized/quasi-randomized trials comparing TXA to placebo or no treatment.
Meta-analysis included 13 studies with a total of 1140 patients assessing blood loss and hemoglobin concentration.
Risk ratios and mean differences were calculated with random-effects models.
TXA patients had less reduction in postoperative hemoglobin (MD: -0.58 g/dL, CI -0.95 to -0.22).
TXA patients experienced less intraoperative blood loss compared to control (MD: -68.7 mL, CI -128.73 to -8.67).
No significant differences in blood transfusion risk (RR: 0.71, CI 0.46-1.10) or thromboembolic events (RR: 1.15, CI 0.89-1.49).